EXCLI J EXCLI Journal 1611-2156 Leibniz Research Centre for Working Environment and Human Factors 2020-2761 10.17179/excli2020-2761 Doc1172 Letter to the editor Which concentrations are optimal for in vitro testing? Albrecht Wiebke * 1 Leibniz Research Centre for Working Environment and Human Factors, Ardeystr. 67, 44139 Dortmund, Germany *To whom correspondence should be addressed: Wiebke Albrecht, Leibniz Research Centre for Working Environment and Human Factors, Ardeystr. 67, 44139 Dortmund, Germany, E-mail: albrecht@ifado.de 18 08 2020 2020 19 1172 1173 05 08 2020 11 08 2020 Copyright © 2020 Albrecht 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.

This article is available from https://www.excli.de/vol19/excli2020-2761.pdf


Dear Editor,

Currently, many research activities in the field of in vitro models focus at predicting human organ toxicity, e.g. of the liver (Gomez-Lechon et al., 2014[4]; Grinberg et al., 2014[6], 2018[5]; Frey et al., 2014[3]), kidney (Li et al., 2013[12], 2014[11]; Sjögren et al., 2018[15]; Sjögren and Hornberg, 2019[16]), heart (Nemade et al., 2018[13]; Chaudhari et al., 2018[2]) or developmental toxicity (Krug et al., 2013[9]; Waldmann et al., 2014[17]; Shinde et al., 2017[14]). All studies face a similar challenge, which is the choice of concentrations for in vitro testing (Leist et al., 2017[10]). This question has recently been discussed in an editorial of the Archives of Toxicology, where the authors pointed out that in vitro tests are usually performed at a concentration range around and above the plasma peak concentrations (Cmax) of a drug in humans (Hengstler et al., 2020[8]). A typical strategy is to test relatively high concentrations, often 20- or even 200-fold higher than the human plasma Cmax. The choice of high concentrations was justified by the observation that usually higher concentrations are required in the culture medium to induce cell damage compared to the Cmax that is known to cause adverse effects in vivo. We made a similar observation in a recent study using human hepatocytes (Albrecht et al., 2019[1]; Gu et al., 2018[7]). The factor by which in vitro concentrations have to be higher than the corresponding in vivo plasma concentration in order to cause similar biological effects in the target cells is the in vitro-in vivo scaling factor.

However, it should be considered that it is not yet clear if all compounds require identical in vitro-in vivo scaling factors. It cannot be excluded that e.g. compounds, whose toxicity depends on specific metabolic pathways may require higher scaling factors than compounds that do not require bio-activation. Moreover, scaling may also depend on the mechanism of toxicity (Hengstler et al., 2020[8]). To gain more insight into the requirements of optimal scaling it is not helpful to test only one or two concentrations, e.g. 20- and/or 200-fold the Cmax and on this basis decide if a compound is positive or negative in the in vitro assay. Rather a concentration-dependent test with not too high dilution factors, such as 2- or at most 3.16-fold is helpful to be able to precisely determine the concentration when toxic effects occur, expressed e.g. as EC10 or EC50. This is a precondition to be able to elucidate if groups of compounds categorized e.g. by metabolic activation or mechanism of action require different scaling factors. A limitation to be overcome in the future is that too few studies established high quality, reproducible concentration response relationships for sufficiently high numbers of test compounds that allow a systematic comparison to the human in vivo situation.

Conflict of interest

The author declares no conflict of interest.

Albrecht W Kappenberg F Brecklinghaus T Stoeber R Marchan R Zhang M Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations Arch Toxicol 2019 93 1609 1637 10.1007/s00204-019-02492-9 Available from: http://dx.doi.org/10.1007/s00204-019-02492-9 Chaudhari U Nemade H Sureshkumar P Vinken M Ates G Rogiers V Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes Arch Toxicol 2018 92 371 381 10.1007/s00204-017-2065-z Available from: http://dx.doi.org/10.1007/s00204-017-2065-z Frey O Misun PM Fluri DA Hengstler JG Hierlemann A Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis Nat Commun 2014 5 4250 10.1038/ncomms5250 Available from: http://dx.doi.org/10.1038/ncomms5250 Gomez-Lechon MJ Tolosa L Conde I Donato MT Competency of different cell models to predict human hepatotoxic drugs Expert Opin Drug Metab Toxicol 2014 10 1553–68 10.1517/17425255.2014.967680 Available from: http://dx.doi.org/10.1517/17425255.2014.967680 Grinberg M Stöber RM Albrecht W Edlund K Schug M Godoy P Toxicogenomics directory of rat hepatotoxicants in vivo and in cultivated hepatocytes Arch Toxicol 2018 92 3517 3533 10.1007/s00204-018-2352-3 Available from: http://dx.doi.org/10.1007/s00204-018-2352-3 Grinberg M Stöber RM Edlund K Rempel E Godoy P Reif R Toxicogenomics directory of chemically exposed human hepatocytes Arch Toxicol 2014 88 2261 2287 10.1007/s00204-014-1400-x Available from: http://dx.doi.org/10.1007/s00204-014-1400-x Gu X Albrecht W Edlund K Kappenberg F Rahnenführer J Leist M Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes Arch Toxicol 2018 92 3505 3515 10.1007/s00204-018-2302-0 Available from: http://dx.doi.org/10.1007/s00204-018-2302-0 Hengstler JG Sjögren AK Zink D Hornberg JJ In vitro prediction of organ toxicity: the challenges of scaling and secondary mechanisms of toxicity Arch Toxicol 2020 94 353 356 10.1007/s00204-020-02669-7 Available from: http://dx.doi.org/10.1007/s00204-020-02669-7 Krug AK Kolde R Gaspar JA Rempel E Balmer NV Meganathan K Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach Arch Toxicol 2013 87 123 143 10.1007/s00204-012-0967-3 Available from: http://dx.doi.org/10.1007/s00204-012-0967-3 Leist M Ghallab A Graepel R Marchan R Hassan R Bennekou SH Adverse outcome pathways: opportunities, limitations and open questions Arch Toxicol 2017 91 3477 3505 10.1007/s00204-017-2045-3 Available from: http://dx.doi.org/10.1007/s00204-017-2045-3 Li Y Kandasamy K Chuah JK Lam YN Toh WS Oo ZY Identification of nephrotoxic compounds with embryonic stem-cell-derived human renal proximal tubular-like cells Mol Pharm 2014 11 1982–90 10.1021/mp400637s Available from: http://doi.org/10.1021/mp400637s Li Y Oo ZY Chang SY Huang P Eng KG Zeng JL An in vitro method for the prediction of renal proximal tubular toxicity in humans Toxicol Res 2013 2 352–62 10.1039/c3tx50042j Available from: http://doi.org/10.1039/c3tx50042j Nemade H Chaudhari U Acharya A Hescheler J Hengstler JG Papadopoulos S Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells Arch Toxicol 2018 92 1507 1524 10.1007/s00204-018-2170-7 Available from: http://dx.doi.org/10.1007/s00204-018-2170-7 Shinde V Hoelting L Srinivasan SP Meisig J Meganathan K Jagtap S Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests Arch Toxicol 2017 91 839 864 10.1007/s00204-016-1741-8 Available from: http://dx.doi.org/10.1007/s00204-016-1741-8 Sjögren AK Breitholtz K Ahlberg E Milton L Forsgard M Persson M A novel multi-parametric high content screening assay in ciPTEC-OAT1 to predict drug-induced nephrotoxicity during drug discovery Arch Toxicol 2018 92 3175–90 10.1007/s00204-018-2284-y Available from: http://doi.org/10.1007/s00204-018-2284-y Sjögren AK Hornberg JJ Compound selection and annotation to validate the predictivity of in vitro toxicity assays for use in drug discovery, in response to Commentary by Dr. Zink (Zink D. Arch Toxicol (2019)) Arch Toxicol 2019 93 225–6 10.1007/s00204-018-2359-9 Available from: http://doi.org/10.1007/s00204-018-2359-9 Waldmann T Rempel E Balmer NV König A Kolde R Gaspar JA Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells Chem Res Toxicol 2014 27 408 420 10.1021/tx400402j Available from: http://dx.doi.org/10.1021/tx400402j